Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any hereditary motor and sensory neuropathy type 6 in which the cause of the disease is a mutation in the MFN2 gene.
Features include always present findings: Distal amyotrophy, Distal muscle weakness, Distal sensory impairment, and Proximal muscle weakness and others; and common findings: Vocal cord paresis. 26 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 4 | Distal muscle weakness, Limb muscle weakness, Proximal muscle weakness |
Eyes | 4 | Color vision defect, Damage to the optic nerve (optic atrophy), Optic disc pallor |
Brain and nerves | 2 | Steppage gait, Hyporeflexia |
Ears | 2 | Tinnitus, Mild neurosensory hearing impairment |
Bones and joints | 2 | Excessive inward curve of the lower back (lumbar hyperlordosis), Sideways curvature of the spine (scoliosis) |
Arms and legs | 1 | Limb muscle weakness |
MFN2 hereditary motor and sensory neuropathy (MFN2-HMSN) is a classic axonal peripheral sensorimotor neuropathy characterized by earlier and more severe involvement of the lower extremities than the upper extremities, distal upper-extremity involvement as the neuropathy progresses, and more prominent motor deficits than sensory deficits. MFN2-HMSN can be caused by a heterozygous pathogenic variant (autosomal dominant inheritance) or biallelic pathogenic variants (semi-dominant inheritance or autosomal recessive inheritance). The phenotypes associated with the different modes of inheritance do not differ significantly .
The age at onset and disease progression of MFN2-HMSN vary within and among families; onset ranges from age one year to the sixth decade. Most ind...
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
MFN2 encodes mitofusin 2 (757 aa). Mitochondrial outer membrane GTPase that mediates mitochondrial clustering and fusion. Highest expression in Heart Left Ventricle (173.4 TPM) and Muscle Skeletal (158.4 TPM).
Neuropathy, hereditary motor and sensory, type 6A is associated with mutations in the MFN2 gene on chromosome 1.
The MFN2 protein participates in Mitofusins trans-interact linking mitochondria prior to fusion pathway.
MFN2 is classified as a druggable target (Enzyme and Transporter categories) with score 0.0.
Autosomal dominant MFN2-HMSN. Variants in certain amino acid residues are always pathogenic, with no evidence of reduced penetrance or variable expressivity (range of phenotypic expression) despite different amino acid substitutions. Examples of different missense changes observed at the same conserved amino acid residue include p.Arg94Trp/Gln, p.Arg104Glu/Trp, p.Ser249Thr/Cys, p.Trp740Ser/Arg . In contrast, variants in other amino acid residues are associated with variable expressivity (early vs later onset of disease) dependent on the amino acid substitution at the same residue. Autosomal dominant vs autosomal recessive variants. No significant genotype-phenotype correlations can be made.
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
The penetrance for AD MFN2-HMSN is considered to be complete. While some individuals with a heterozygous MFN2 pathogenic variant are asymptomatic and have only mild findings on examination at the time of diagnosis, the disease may prove to be late onset in these instances .
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
Formal diagnostic criteria for MFN2 hereditary motor and sensory neuropathy have not been established.
MFN2 hereditary motor and sensory neuropathy (MFN2-HMSN) should be considered in individuals with the following clinical and neurophysiologic findings. Note: No specific findings distinguish MFN2-HMSN from other inherited hereditary motor and sensory neuropathies.
Clinical findings
Onset before age ten years (although a wide range has been reported)
Involvement of the lower extremities earlier and more severely than the upper extremities
Involvement of the distal upper extremities as the neuropathy progresses
Motor deficits more prominent than sensory deficits
Optic atrophy (~7% in the autosomal dominant form, and ~20% in the autosomal recessive form)
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
All hereditary motor and sensory neuropathy (HMSN) forms in which axonal phenotypes have been reported, including PMP22-HMSN, MPZ-HMSN, and GJB1-HMSN (see GJB1 Disorders) need to be considered in the differential diagnosis of MFN2-HMSN. See Charcot-Marie-Tooth Hereditary Neuropathy Overview. MFN2 pathogenic variants are by far the most common cause of autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2). As many as one third of all individuals with CMT2 with a positive family history have a pathogenic variant in MFN2 . Thus, testing of MFN2 is probably the first genetic test to consider in families with an axonal neuropathy demonstrating male-to-male transmission.
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
Genetic testing for MFN2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for neuropathy, hereditary motor and sensory, type 6A has been reported in the published literature.
No approved treatments are currently available for neuropathy, hereditary motor and sensory, type 6A. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with MFN2 hereditary motor and sensory neuropathy (MFN2-HMSN), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with MFN2 Hereditary Motor and Sensory Neuropathy
System/Concern | Evaluation | Comment |
|---|---|---|
neuropathy | Neurologic exam | To determine extent of weakness atrophy, pes cavus, gait stability, sensory loss EMG w/NCV |
Musculoskeletal | Orthopedics / physical medicine rehab / PT OT eval | To incl assessment of:; Gross motor fine motor skills need for PT (to improve gross motor skills) /or OT (to improve fine motor skills); Feet for evidence of pes cavus, need for AFOs, specialized shoes; Mobility, ADL, need for adaptive devices; Need for handicapped parking |
Optic atrophy | Ophthalmologic exam incl VEP | To incl visual acuity, color vision testing, visual field testing for evidence of central scotomas Genetic |
counseling | By genetics professionals1 | To obtain a pedigree inform affected persons their families re nature, MOI, implications of MFN2-HMSN to facilitate medical personal decision making Family support resources |
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
Obesity, which makes walking more difficult, should be avoided. Medications that are toxic or potentially toxic to persons with CMT comprise a spectrum of risk ranging from definite high risk to negligible risk. See the Charcot-Marie-Tooth Association website for an up-to-date list.
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
View trials for neuropathy, hereditary motor and sensory, type 6A
Table 4. Recommended Surveillance for Individuals with MFN2 Hereditary Motor and Sensory Neuropathy
System/Concern | Evaluation | Frequency |
|---|---|---|
Imaging | MRI of legs to assess amount location of fat replacing muscles1 | Specialized centers only, every few yrs |
Foot exam | For pressure sores or poorly fitting footwear | Annually |
Vision | Those w/o visual manifestations | Routine ophthalmologic exam |
Those w/opticatrophy | Assessment of visual acuity, visual fields | Per treating ophthalmologist Assessment of low vision aids |
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
Phenotype severity distribution: 6 always present features, 1 common feature.
No clinical trials have been registered for neuropathy, hereditary motor and sensory, type 6A.
13 publications have been identified in PubMed for neuropathy, hereditary motor and sensory, type 6A. Research spans Case Report / Case Series (38%), Review / Meta-Analysis (15%), and Basic Science / Preclinical (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 5 | 38% |
Research summaries | 2 | 15% |
Laboratory research | 2 | 15% |
Disease patterns and progression | 2 | 15% |
Testing and diagnosis research | 1 | 8% |
New treatment approaches | 1 | 8% |
Tsuruda T (2026). [PMID: 41711216](https://pubmed.ncbi.nlm.nih.gov/41711216/). *ESC Heart Fail*. [Epidemiology / Natural History]
Sobanska A (2026). [PMID: 41507865](https://pubmed.ncbi.nlm.nih.gov/41507865/). *BMC neurology*. [Diagnostic / Biomarker]
Munir A (2025). [PMID: 41253761](https://pubmed.ncbi.nlm.nih.gov/41253761/). *Human genome variation*. [Basic Science / Preclinical]
Fu X (2025). [PMID: 40849231](https://pubmed.ncbi.nlm.nih.gov/40849231/). *Journal of neuromuscular diseases*. [Basic Science / Preclinical]
Cesaroni CA (2025). [PMID: 41300731](https://pubmed.ncbi.nlm.nih.gov/41300731/). *Genes*. [Review / Meta-Analysis]
Kikuchi K (2025). [PMID: 40636623](https://pubmed.ncbi.nlm.nih.gov/40636623/). *Cureus*. [Review / Meta-Analysis]
Mohammed S (2024). [PMID: 39604983](https://pubmed.ncbi.nlm.nih.gov/39604983/). *Journal of medical case reports*. [Case Report / Case Series]
Tomaselli PJ (2024). [PMID: 38409938](https://pubmed.ncbi.nlm.nih.gov/38409938/). *European journal of neurology*. [Case Report / Case Series]
Silsby M (2024). [PMID: 38051345](https://pubmed.ncbi.nlm.nih.gov/38051345/). *Journal of neurology*. [Epidemiology / Natural History]
Xu L (2024). [PMID: 37890998](https://pubmed.ncbi.nlm.nih.gov/37890998/). *Journal of medical genetics*. [Case Report / Case Series]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 6:03 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Evaluation |
Frequency Neurologic |
Imaging | MRI of legs to assess amount location of fat replacing muscles1 | Specialized centers only, every few yrs |
Foot exam | For pressure sores or poorly fitting footwear | Annually |
Vision | Those w/o visual manifestations | Routine ophthalmologic exam |
Those w/opticatrophy | Assessment of visual acuity, visual fields | Per treating ophthalmologist Assessment of low vision aids |